Clinical trial NCT03531372: Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn.
Official title: Efficacy and Safety of Mipolixin® Compared to Poliprotect ® in the Relief of Symptoms of Moderate Functional Dyspepsia and Heartburn: A Randomized, Double-blind, Parallel Group,Non-inferiority Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dyspepsia
Heartburn
Lead sponsor: Aboca Spa Societa' Agricola
Sponsor class: INDUSTRY
Collaborators: name: La Sociedad Española de Médicos de Atención Primaria
name: Dynamic
First posted: 2018-05-21
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of the clinical efficacy of two medical devices, Mipolixin® and Poliprotect®, in improving the overall symptom severity of functional dyspesia and/or heartburn


Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent, preferably in writing or, failing that, orally in front of a witness, before any study procedure is performed.
* Male and female patients aged 18 to 75 years old (inclusive).
* Patients with symptoms of functional dyspepsia (according to the Rome IV criteria) of moderate severity (VAS score between 30 mm and 70 mm) and/or bothersome heartburn within 2 and 14 days prior to the screening/baseline visit.

  o According to the current Rome IV diagnostic criteria, functional dyspepsia is defined as one or more of the following symptoms: postprandial fullness (classified as postprandial distress syndrome), early satiation (inability to finish a normal sized meal, also classified as postprandial distress syndrome), and epigastric pain or burning (classified as epigastric pain syndrome).
* Ability of the patients (according to the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects.
* Patients who agree not to alter their diet in any way for the duration of the trial and to maintain it at steady state.
* Patients who agree not to make any major lifestyle changes during the trial.
* Willingness to comply with all the study procedures and schedule.
* Chronic therapies (if not related to the gastroenterological pathologies object of the study, according to the opinion of the investigator) are allowed, if the regimen is maintained stable during the whole study.

Exclusion Criteria:

* Declines or unable to provide informed consent.

  - Disease or health condition
* Patient presenting at least one of the following symptoms or conditions at screening: anemia, chronic gastrointestinal bleeding, progressive unintentional weight loss, epigastric mass, anorexia, persistent or recurrent vomiting, dysphagia or odynophagia, porphyria, hypophosphatemia, and/or cachexia.
* Patients presenting with at least of the following gastrointestinal conditions at screening: erosive GERD, Barrett's oesophagus or oesophageal stricture, active or healing gastroduodenal ulcer (except scars), history of gastric, duodenal or esophageal surgery, symptomatic gallstone, and/or other gastrointestinal disease such as gastroenteritis, inflammatory bowel disease, celiac disease and/or colorectal cancer.
* Patients with known malignancy disease, infectious disease or severe heart or pulmonary disease.
* Patients with known severe liver or kidney disease (AST/SGOT, ALT/SGPT \>2 upper limits of normal, serum creatinine \>1.5 mg/dl).
* Patients with mental or metabolic disorders and any other disease that according to the physician can compromise the patient´s safety and/or patient´s study compliance.

  - Treatments
* Patients receiving any treatment (pharmacological or medical device) for heartburn or dyspeptic symptoms within the last 14 days prior to randomization.
* Patients receiving any drugs that could affect symptoms or study evaluation such antacids, PPIs, H2RAs, prokinetics, and/or gastric mucosal protectants at baseline and/or taken within the last 14 days prior to randomization.
* Patients receiving any drugs that could affect symptoms or the study as antibiotics, NSAIDs, anticholinergics and/or cholinergic agents.

Note: Patients will be asked to avoid any drugs of the above mentioned since the beginning of the study (baseline visit) until the end of the study.

* Patients under triple therapy or eradication therapy against Helicobacter pylori.
* Patients planned for long-term new therapies with anti-anxiety agents, glucocorticosteroids and anti-inflammatory agents during study period.
* Known hypersensitive or intolerance to any components of the study medical devices.
* Previous intake of any of the study medical devices.

  - Other general conditions
* Patients who are unable to understand or are unwilling to sign an informed consent form.
* Unable or unwilling to complete all required screening and/or follow-up assessments.
* Unable to understand and complete self-administered scales/questionnaires planned to be used in the study.
* Participation in interventional research studies of investigational medicinal or device products (ongoing or terminated less than 30 days before screening)
* Patients with active alcohol or drug addiction or any other condition that, in the investigator's opinion, would interfere with their ability to comply with the study requirements.
* Patients with any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
* Pregnant or nursing (lactating) women;
* Women of childbearing potential and sexually active: they must be willing to use at least one acceptable effective contraceptive measure (- progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action , - male or female condom with or without spermicide, - cap, diaphragm or sponge with spermicide). Pregnancy test will be performed at screening and at the final/premature withdrawal visit. The use of contraception in male patients is not required.

Primary outcomes:
measure: Change in overall symptom severity from baseline (day 0) to day 14 between the two study arms
timeFrame: Day 0 and Day 14
Secondary outcomes:
measure: Responders from baseline to day 3 and day 7
timeFrame: Day 0, Day 3 and Day 7
measure: Self-assessment severity of individual specific symtoms
timeFrame: Day 0, Day 1, Day 3, Day 7 and Day 14
measure: Change in the score of GOS scale from baseline to day 1
timeFrame: Day 0 and Day 14
measure: Incidence of AEs during study treatment
timeFrame: Day 0 to Day 14
measure: Incidence of AEs and clinical findings during study period
timeFrame: Day 0 to Day 28
measure: Patient satisfaction (treatment administration)
timeFrame: Day 3, Day 7 and Day 14
measure: Patient satisfaction (taste)
timeFrame: Day 3, Day 7 and Day 14
measure: Treatment compliance
timeFrame: Day 0 to Day 14
Other outcomes:
Locations:
city: Albuñol
country: Spain
facility: CS Albuñol
city: El Prat De Llobregat
country: Spain
facility: CS Disset de Setembre
city: Madrid
country: Spain
facility: CS Montesa
city: Madrid
country: Spain
facility: CS Goya
city: Madrid
country: Spain
facility: Primary Care Centre Eloy Gonzalo
city: Madrid
country: Spain
facility: CS Comillas
city: Madrid
country: Spain
facility: CS Baviera
city: Parla
country: Spain
facility: CS Las Americas
city: Parla
country: Spain
facility: CS San Blas
city: Parla
country: Spain
facility: CS Isabel II
city: Perales de Tajuña
country: Spain
facility: Consultorio Local Perales de Tajuña
Study officials:
References: